

Dr Giorgio ROSCIGNO

Chief Operating Officer

African Society for Laboratory Medicine

Dr Roscigno has 20 years experience in the pharmaceutical industry, in medical and clinical research of antinfectives. He joined the Industry after 5 years field medical experience in Ethiopia, Sudan and the Democratic Republic of Congo. He has been at different times, the Medical Director for Africa, Asia, the European Clinical Research Director for Antinfectives, and finally the International Medical Director for Antinfectives with Aventis in Paris (France)

During his years with Industry, Dr. Roscigno has been closely associated with the clinical work and the subsequent registration (including FDA) of all the Tuberculosis fixed dose combinations containing rifampin. He also contributed to the clinical development of rifapentine, a long acting rifamycin, approved by FDA in 1998.

Dr Roscigno has also led the clinical research work on DFMO eflornithine, for the treatment of sleeping sickness, and the coordination of the African multicenter clinical trial, in collaboration with TDR. The outcome of this trial represented the clinical package for FDA approval in 1992.

In 2000, Dr Roscigno was among the founding members of the Global Alliance for TB Drug Development, a non for profit public-private partnership dedicated to the discovery of new TB drugs. He left the industry and joined the GATB, initially as Acting Chief Executive Officer, then Strategic Development Director.

Dr Roscigno joined FIND at its launch in 2003 as the first Chief Executive Officer. In this position, he has overseen the growth of the organization, the development of 5 new TB diagnostic tools approved by WHO, the roll-out of these tools in 27 countries, as well as the establishment of ambitious programs in malaria and sleeping sickness.

On October 1st 2011, Dr. Roscigno joined the top leadership team of the newly launched African Society of Laboratory Medicine (ASLM) as Chief Operating Officer.